Peptide Phase 2 Licensing Benchmarks
Deal economics across 15 transactions with 11 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$125M
11 deals with terms
Median Total Value
$1.6B
Upfront + milestones
Royalty Range
6.6%--14.9%
Average low--high
Deal Count
15
2019--2026
The median upfront payment for phase 2 peptide licensing deals is $125M, based on 11 deals with disclosed terms from 2019--2026. Total deal values (including milestones) reach a median of $1.6B. Royalty rates typically range from 6.6% to 14.9%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Carmot Therapeutics | Roche | 2023 | $2.7B | $2.7B |
| Zealand Pharma | Roche | 2024 | $1.6B | $5.3B |
| Zealand Pharma | Boehringer Ingelheim | 2022 | $350M | $1.6B |
Showing 3 of 11 deals with disclosed terms. Full comp set available in the report.
Full Peptide phase-2 Comp Set
Get the complete analysis -- 11 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific peptide asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2019--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.